Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 11, 2024
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 –
– Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 –
Read more at globenewswire.com10.52
-0.02 (-0.19%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
